Last reviewed · How we verify

Conventional paclitaxel or Taxol — Competitive Intelligence Brief

Conventional paclitaxel or Taxol (Conventional paclitaxel or Taxol) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Taxane; microtubule stabilizer. Area: Oncology.

phase 3 Taxane; microtubule stabilizer β-tubulin Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Conventional paclitaxel or Taxol (Conventional paclitaxel or Taxol) — Jina Pharmaceuticals Inc.. Paclitaxel stabilizes microtubules by binding to β-tubulin, preventing their depolymerization and causing cell cycle arrest and apoptosis in cancer cells.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Conventional paclitaxel or Taxol TARGET Conventional paclitaxel or Taxol Jina Pharmaceuticals Inc. phase 3 Taxane; microtubule stabilizer β-tubulin
albendazole and praziquantel albendazole and praziquantel R-Evolution Worldwide S.r.l. Impresa Sociale marketed Anthelmintic combination β-tubulin (albendazole); calcium channels (praziquantel)
Paclitaxel protein bound Paclitaxel protein bound Barts & The London NHS Trust marketed Taxane; microtubule stabilizer β-tubulin (microtubule)
Albendazole plus Praziquantel Albendazole plus Praziquantel Navrongo Health Research Centre, Ghana marketed Antihelmintic combination β-tubulin (albendazole); calcium channels (praziquantel)
VLI VLI Spectrum Pharmaceuticals, Inc marketed Vinca alkaloid β-tubulin
Paclitaxel (Pac) Paclitaxel (Pac) Aravive, Inc. marketed Taxane; microtubule stabilizer β-tubulin / microtubules
Cabazitaxel (XRP6258) Cabazitaxel (XRP6258) Sanofi marketed Taxane; microtubule stabilizer β-tubulin (microtubule)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Taxane; microtubule stabilizer class)

  1. Sanofi · 2 drugs in this class
  2. Aravive, Inc. · 1 drug in this class
  3. Athenex, Inc. · 1 drug in this class
  4. Barts & The London NHS Trust · 1 drug in this class
  5. BeyondSpring Pharmaceuticals Inc. · 1 drug in this class
  6. Bio-Thera Solutions · 1 drug in this class
  7. Dai, Guanghai · 1 drug in this class
  8. Fujian Medical University · 1 drug in this class
  9. Guangzhou Double Bioproducts Co., Ltd · 1 drug in this class
  10. H. Lee Moffitt Cancer Center and Research Institute · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Conventional paclitaxel or Taxol — Competitive Intelligence Brief. https://druglandscape.com/ci/conventional-paclitaxel-or-taxol. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: